FDA accepts Teva's NDA for albuterol inhaler

|About: Teva Pharmaceutical In... (TEVA)|By:, SA News Editor

The U.S. FDA has accepted for standard review Teva Pharmaceutical Industries' (TEVA +0.9%) NDA for its albuterol multi-dose dry powder inhaler (MDPI) as a treatment for reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients at least 12 years old.

Teva expects a response from the regulator by late Q1 2015.